Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Orion PharmaDHA:ORIONPHARM +0.66%72 Receivables Turnover is 0.34 as of Mar. 2026. GuruFocus rates DHA:ORIONPHARM with a GF Score™ of 72/100 and a GF Value™ of BDT20.16 (Significantly Overvalued). The stock has 8 warning signs investors should review. Among 410 Utilities - Independent Power Producers companies, Orion Pharma ranks worse than 91.22% on this metric.
The Receivables Turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by average Accounts Receivable. An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. Orion Pharma's Revenue for the
three
months ended in Mar. 2026 was BDT1,487 Mil. Orion Pharma's average Accounts Receivable for the
three
months ended in Mar. 2026 was BDT4,332 Mil.
Hence, Orion Pharma's Receivables Turnover for the
three
months ended in Mar. 2026 was 0.34.
An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. This metric is commonly used to compare companies within the same industry to check whether they are on par with their competitors.
Orion Pharma Receivables Turnover Related Terms
Orion Pharma Receivables Turnover Historical Data
* Premium members only.
The historical data trend for Orion Pharma's Receivables Turnover can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
DHA:ORIONPHARM vs CEG, VST, NRG: Receivables Turnover Comparison
For the Utilities - Independent Power Producers subindustry, Orion Pharma's Receivables Turnover, along with its competitors' market caps and Receivables Turnover data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Orion Pharma Receivables Turnover vs Utilities - Independent Power Producers Industry
For the Utilities - Independent Power Producers industry and Utilities sector, Orion Pharma's Receivables Turnover distribution charts can be found below:
* The bar in red indicates where Orion Pharma's Receivables Turnover falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Orion Pharma (DHA:ORIONPHARM) has a Receivables Turnover of 0.34 as of Mar. 2026. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on Orion Pharma and its competitors. According to the industry distribution chart, Orion Pharma ranks #374 out of 410 companies in the Utilities - Independent Power Producers industry, placing it in the top 91.2%.
Is Orion Pharma's Receivables Turnover too high?
Orion Pharma's current Receivables Turnover is 0.34. The Utilities - Independent Power Producers industry median Receivables Turnover is 5.73. Orion Pharma's value of 0.34 is 94.1% below this industry median. Based on the distribution chart, Orion Pharma ranks #374 out of 410 companies in the Utilities - Independent Power Producers industry, which is in the bottom quartile relative to peers. Overall, Orion Pharma has a GF Score™ of 72/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Orion Pharma's Receivables Turnover compare to CEG and VST?
According to the Utilities - Independent Power Producers industry distribution chart, Orion Pharma ranks #374 out of 410 companies for Receivables Turnover. This places Orion Pharma in the lower half of its industry. The industry median Receivables Turnover is 5.73. Orion Pharma's value of 0.34 is 94.1% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Receivables Turnover for an Utilities - Independent Power Producers company?
The median Receivables Turnover among Utilities - Independent Power Producers companies is 5.73, based on 410 companies in the industry. Companies in the top quartile (top 25%) have a Receivables Turnover significantly above this median, while those in the bottom quartile fall well below. However, Receivables Turnover should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Orion Pharma's current Receivables Turnover of 0.34 is 94.1% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Receivables Turnover mean?
A high Receivables Turnover can signal that a stock is expensive relative to its fundamentals. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on Orion Pharma and its competitors. For the Utilities - Independent Power Producers industry, the median Receivables Turnover is 5.73 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Orion Pharma's current Receivables Turnover is 0.34. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Orion Pharma stock overvalued right now?
Based on GuruFocus' analysis, Orion Pharma (DHA:ORIONPHARM) is currently considered Significantly Overvalued. The stock's GF Value™ is BDT20.16, compared to a current price of BDT30.30 — trading 50.3% above its estimated fair value. The current Receivables Turnover is 0.34 and 94.1% below the Utilities - Independent Power Producers industry median of 5.73. Orion Pharma's overall GF Score™ is 72/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Receivables Turnover calculated?
Receivables Turnover is calculated from a company's financial statements. For Orion Pharma (DHA:ORIONPHARM), the current Receivables Turnover is 0.34 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Orion Pharma (DHA:ORIONPHARM) Overvalued in 2026?
Based on GuruFocus' analysis, Orion Pharma stock appears to be overvalued.
The current stock price of BDT30.30 is trading 50.3% above its estimated GF Value™ of BDT20.16.
GuruFocus considers Orion Pharma to be Significantly Overvalued.
Key valuation signals for DHA:ORIONPHARM:
Receivables Turnover: 0.34
GF Value™: BDT20.16 vs. price of BDT30.30 (50.3% above fair value)
Industry Position: 94.1% below the Utilities - Independent Power Producers median (#374 of 410)
No single metric tells the full story. See the DHA:ORIONPHARM stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Orion Pharma Ltd is a pharmaceutical company engaged in the creation and discovery, development, manufacturing, and marketing of pharmaceutical products, including vaccines and health-related consumer products. The company produces diversified dosage forms such as tablets, capsules, syrups, solutions, suspensions, powder for suspensions, creams, ointments, and injections under therapeutic categories including cardiovascular, antiulcerant, antiasthmatic, antihistamine, NSAIDs, antibiotic, antifungal, laxatives, anticancer, vitamins, and minerals. In addition, the company is involved in power generation activities and generates maximum revenue from pharmaceutical activities. The group principally carries out its business operations and markets its products in Bangladesh.
72GF Score
Get the complete analysis for DHA:ORIONPHARM
Receivables Turnover is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
DHA:ORIONPHARM has been successfully added to your 
